Strain Name:

FVB/N-Tg(tetO-BCR/ABL1)2Dgt/J

Stock Number:

006202

Order this mouse

Availability:

Cryopreserved - Ready for recovery

Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Type Coisogenic; Mutant Strain; Transgenic;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Specieslaboratory mouse
GenerationN?+N1F2pN1
Generation Definitions
 
Donating Investigator Daniel G. Tenen,   Beth Israel Deaconess Medical Center

Description
Hemizygotes are viable, fertile, normal in size, and do not display any behavioral abnormalities. Transgene expression is directed by the tetracycline-responsive element (TRE; tetO). When hemizygotes are bred with another transgenic mouse expressing either reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA) under the regulation of tissue-specific promoters , BCR-ABL1 fusion protein expression can be regulated in the appropriate tissue of the bitransgenic offspring with the tetracycline analog, doxycycline.

These mice originally were designed to be bred with transgenic mice harboring a Tal1-tTA transgene (see Stock No. 006209), creating double transgenic offspring as a model for studies of the Philadelphia chromosome and inducible chronic myeloid leukemia.

When bred to a strain expressing tTA in the epithelial cells of secretory organs and skin (see Stock No. 002618 - Tg(MMTVtTa)1Mam), this mutant mouse strain may be useful in studies of leukemia.

When bred to a strain expressing tTA in thebone marrow hematopoietic stem cells and in common myeloid progenitors (see Stock No. 017722 - Tg(Tal1-tTA)19Dgt), this mutant mouse strain may be useful in studies of chronic myeloid leukemia.

Development
A transgene was generated containing a human p210 BCR-ABL1 fusion protein cDNA sequence under transcriptional control of the tetracycline-responsive element (TRE; tetO) sequence fused to a minimal cytomegalovirus (hCMV) promoter. The transgene was injected into fertilized FVB/N eggs. Transgenic offspring (founder line 2) were maintained by breeding transgenic mice to either FVB/N inbred mice or wildtype siblings for many generations prior to arrival at The Jackson Laboratory.

Control Information

  Control
   Noncarrier
   001800 FVB/NJ
 
  Considerations for Choosing Controls

Related Strains

Strains carrying other alleles of ABL1
017833   B6.Cg-Tg(BCR/ABL)623Hkp/J
014544   STOCK Tg(tetO-ABL1*P242E*P249E)CPdav/J
View Strains carrying other alleles of ABL1     (2 strains)

Strains carrying other alleles of BCR
017833   B6.Cg-Tg(BCR/ABL)623Hkp/J
View Strains carrying other alleles of BCR     (1 strain)

Strains carrying other alleles of tetO
008079   129S-Ppargtm2Yba/J
016176   B6(Cg)-Tg(tetO-Per2)2Jt/J
023757   B6(Cg)-Tg(tetO-tetX,lacZ)1Gogo/UmriJ
009602   B6.129S4(Cg)-Kcnn2tm2Jpad/J
009603   B6.129S4-Kcnn3tm1Jpad/J
017983   B6.Cg-Col1a1tm9(tetO-Dnmt3b_i1)Jae Gt(ROSA)26Sortm1(rtTA*M2)Jae/J
014588   B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm6(tetO-MSI2)Jae/J
023749   B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae Tg(tetO-Pou5f1,-Sox2,-Klf4,-Myc)1Srn/J
014648   B6.Cg-Gt(ROSA)26Sortm37(H1/tetO-RNAi:Taz)Arte/ZkhuJ
006361   B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J
016998   B6.Cg-Tg(TetO-Axin1,EGFP)TA6Cos/J
003762   B6.Cg-Tg(tetFosb)4468Nes/J
007051   B6.Cg-Tg(tetO-APPSwInd)102Dbo/Mmjax
007052   B6.Cg-Tg(tetO-APPSwInd)107Dbo/Mmjax
007049   B6.Cg-Tg(tetO-APPSwInd)885Dbo/Mmjax
007618   B6.Cg-Tg(tetO-Arntl)1Jt/J
017555   B6.Cg-Tg(tetO-CALY)5Cber/J
024114   B6.Cg-Tg(tetO-CHRM4*)2Blr/J
008277   B6.Cg-Tg(tetO-Clockm1Jt)CL57Jt/J
008468   B6.Cg-Tg(tetO-DTA)1Gfi/J
017791   B6.Cg-Tg(tetO-Hamp)2181Nca/J
009344   B6.Cg-Tg(tetO-Ifng)184Pop/J
009136   B6.Cg-Tg(tetO-Kcnj2,lacZ)1Gogo/J
013583   B6.Cg-Tg(tetO-LRRK2)C7874Cai/J
020652   B6.Cg-Tg(tetO-Mif)279Aren/J
017331   B6.Cg-Tg(tetO-Ppp3ca*)11255Kndl/J
017332   B6.Cg-Tg(tetO-Ppp3ca*)13967Kndl/J
017330   B6.Cg-Tg(tetO-TAg*)175Kndl/J
006234   B6.Cg-Tg(tetO-cre)1Jaw/J
005738   B6.FVB-Tg(tetO-EGFP,-Tgfbr2)8Mcle/J
006911   B6;129-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm2(tetO-Pou5f1)Jae/J
011001   B6;129S4-Col1a1tm1(tetO-Pou5f1,-Klf4,-Sox2,-Myc)Hoch/J
016836   B6;129S4-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm7(tetO-HIST1H2BJ/GFP)Jae/J
012433   B6;C3-Tg(ACTA1-rtTA,tetO-cre)102Monk/J
002709   B6;C3-Tg(TettTALuc)1Dgs/J
023598   B6;C3-Tg(tetO-AIMP2)630Tmd/J
016841   B6;C3-Tg(tetO-TARDBP)12Vle/J
014650   B6;C3-Tg(tetO-TARDBP*)4Vle/J
012450   B6;D2-Tg(tetO-SNCA)1Cai/J
008344   B6;DBA-Tg(Fos-tTA,Fos-EGFP*)1Mmay Tg(tetO-lacZ,tTA*)1Mmay/J
008082   B6;SJL-Tg(Tagln-tTA)1Mrab Tg(tetO-Mcpt1)1Mrab/J
010575   B6;SJL-Tg(tetO-Egfr*)2-9Jek/J
010577   B6;SJL-Tg(tetO-Erbb2*)8-4Jek/J
002621   B6;SJL-Tg(tetop-lacZ)2Mam/J
006004   B6C3-Tg(tetO-APPSwInd)885Dbo/Mmjax
016976   B6C3-Tg(tetO-SNCA*A53T)33Vle/J
018913   B6N.Cg-Tg(tetO-GFP,-lacZ)G3Rsp/J
006244   C.Cg-Tg(tetO-cre)1Jaw/J
017719   C3HeB/FeJ-Tg(tetO-TAg)1Efr/J
017955   C57BL/6-Tg(Gfap-rtTA,tetO-MAOB,-lacZ)1Jkan/J
005706   C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J
006618   C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J
017613   C57BL/6-Tg(tetO-Cdkn1b)1Scpr/J
013729   C57BL/6-Tg(tetO-EDN1,-lacZ)9Mhus/J
016260   C57BL/6-Tg(tetO-Fbxl21)38Jt/J
016179   C57BL/6-Tg(tetO-Fbxl21*)11Jt/J
010713   C57BL/6-Tg(tetO-GFP/tetX)5696Stl/J
013728   C57BL/6-Tg(tetO-NOS2,-lacZ)240iMhus/J
016181   C57BL/6-Tg(tetO-Nr1d1)1Schb/J
008278   C57BL/6J-Tg(tetO-Clock)1Jt/J
016580   C57BL/6J-Tg(tetO-Usf1)2Jt/J
021065   FVB(C)-Tg(tetO-Npc1/YFP)1Mps/J
017542   FVB-Tg(Myh6/tetO-ATP2B4)1Jmol/J
016571   FVB-Tg(Myh6/tetO-Gata6)2Jmol/J
014155   FVB-Tg(Myh6/tetO-Itpr1)22.3Jmol/J
014153   FVB-Tg(Myh6/tetO-Itpr2)3.11Jmol/J
014154   FVB-Tg(Myh6/tetO-Itpr2)4.9Jmol/J
012684   FVB-Tg(Myh6/tetO-POSTN)22.1Jmol/J
010580   FVB-Tg(Myh6/tetO-PRKCA*)1Jmk/J
013156   FVB-Tg(tetO-CDK5R1*)1Vln/J
013777   FVB-Tg(tetO-Cacna1g)1Jmol/J
013778   FVB-Tg(tetO-Cacnb2)1Jmol/J
013779   FVB-Tg(tetO-Cacnb2)2Jmol/J
013780   FVB-Tg(tetO-Cib1)1Jmol/J
010578   FVB-Tg(tetO-Dusp6)1Jmol/J
017333   FVB-Tg(tetO-Gnai2*,-lacZ)382Kndl/J
008685   FVB-Tg(tetO-Kdr*)4377.5Rwng/J
023397   FVB-Tg(tetO-Lmnb1)AF1Yfu/J
015815   FVB-Tg(tetO-MAPT*P301L)#Kha/JlwsJ
008695   FVB-Tg(tetO-MET)23Rwng/J
012387   FVB-Tg(tetO-Ppargc1a)1Dpk/J
012385   FVB-Tg(tetO-Ppargc1b)7Dpk/J
022979   FVB-Tg(tetO-Thbs4)17.7Jmol/J
006439   FVB-Tg(tetO/CMV-KRAS*G12C)9.1Msmi/J
019038   FVB.Cg-Tg(tetO-GLI1)10Rup/Mmjax
019039   FVB.Cg-Tg(tetO-KLF4)32831Rup/Mmjax
008244   FVB.Cg-Tg(tetO-cre)1Jaw/J
012459   FVB/N-Tg(Myh6*/tetO-Capn1)L2Gwd/J
005941   FVB/N-Tg(tetO-Aurkb,lacZ)41Kra/J
014547   FVB/N-Tg(tetO-Fasl)BDepa/J
019376   FVB/N-Tg(tetO-MYC)36aBop/J
022938   FVB/N-Tg(tetO-Wnt5a)17Rva/J
003315   FVB/N-Tg(tetORo1-lacZ)3Conk/J
005076   NOD.Cg-Tg(tetO-EGFP/FADD)1Doi/DoiJ
006999   STOCK Dbttm1Geh Tg(Cebpb-tTA)5Bjd Tg(tetO-DBT)A1Geh/J
011004   STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/J
011011   STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm4(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/J
011013   STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm5(tetO-Pou5f1,-Klf4,-Myc)Jae/J
018999   STOCK Gt(ROSA)26Sortm1(tTA,tetO-Mir155)Fjsl/J
017596   STOCK Gt(ROSA)26Sortm1.1(rtTA,EGFP)Nagy Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN2*delta7)4299Ahmb Tg(tetO-SMN2,-luc)#aAhmb/J
017597   STOCK Gt(ROSA)26Sortm1.1(rtTA,EGFP)Nagy Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN2*delta7)4299Ahmb Tg(tetO-SMN2,-luc)#bAhmb/J
024854   STOCK Tg(Camk2a-tTA)1Mmay Tg(tetO-MAPT*P301L)#Kha/J
008755   STOCK Tg(Ins2-rtTA)2Efr Tg(teto-DTA)1Gfi/J
012477   STOCK Tg(Myh6*/tetO-GCaMP2)1Mik/J
016572   STOCK Tg(Myh6/tetO-Gata4)1Jmol/J
014544   STOCK Tg(tetO-ABL1*P242E*P249E)CPdav/J
014093   STOCK Tg(tetO-CHRM3*)1Blr/J
008790   STOCK Tg(tetO-DISC1*)1001Plet/J
008168   STOCK Tg(tetO-DTA)1Gfi/J
017755   STOCK Tg(tetO-GCAMP2)12iRyu/J
016970   STOCK Tg(tetO-HCV)1Mlch/Mmjax
005104   STOCK Tg(tetO-HIST1H2BJ/GFP)47Efu/J
005699   STOCK Tg(tetO-Ipf1,EGFP)956.6Macd/J
005728   STOCK Tg(tetO-Ipf1,lacZ)958.1Macd/J
012441   STOCK Tg(tetO-LRRK2*G2019S)E3Cai/J
017918   STOCK Tg(tetO-MAML1*/EGFP)2Akar/J
017599   STOCK Tg(tetO-SMN2,-luc)#aAhmb/J
017600   STOCK Tg(tetO-SMN2,-luc)#bAhmb/J
012442   STOCK Tg(tetO-SNCA*A53T)E2Cai/J
006224   STOCK Tg(tetO-cre)1Jaw/J
017906   STOCK Tg(tetO-hop/EGFP,-COP4/mCherry)6Kftnk/J
012345   STOCK Tg(tetO-tdTomato,-Syp/EGFP*)1.1Luo/J
012449   STOCK Tg(teto-LRRK2)C7874Cai/J
View Strains carrying other alleles of tetO     (123 strains)

Additional Web Information

Tet Expression Systems

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Characteristics of this human disease are associated with transgenes and other mutation types in the mouse.
Leukemia, Chronic Myeloid; CML
- Potential model based on transgenic expression of an ortholog of a human gene that is associated with this disease. Phenotypic similarity to the human disease has not been tested.
Leukemia, Acute Lymphoblastic; ALL   (BCR)
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

The following phenotype relates to a compound genotype created using this strain.
Contact JAX® Services jaxservices@jax.org for customized breeding options.

Tg(tetO-BCR/ABL1)2Dgt/0 Tg(MMTVtTA)1Mam/0

        involves: C57BL/6 * FVB/N * SJL
  • mortality/aging
  • premature death
    • upon withdrawal of tetracycline (TET), expression of BCR/ABL results in development of lethal leukemia; 100% of bitransgenic mice die by ~27 days   (MGI Ref ID J:72377)
  • hematopoietic system phenotype
  • anemia
    • severe anemia develops in peripheral blood without TET treatment   (MGI Ref ID J:72377)
  • decreased platelet cell number
    • severe thrombocytopenia in peripheral blood develops when TET treatment is stopped   (MGI Ref ID J:72377)
  • enlarged spleen
    • spleen becomes massively enlarged when TET treatment is stopped   (MGI Ref ID J:72377)
  • increased leukocyte cell number
    • increased peripheral blood leukocyte count is observed 6-10 days after TET withdrawal; blood shows presence of cells resembling immature lymphocytes   (MGI Ref ID J:72377)
    • when TET is given to mice in advanced stages of disease, WBC counts normalize in 48-72 hours, lymphoblasts are not detected in peripheral blood   (MGI Ref ID J:72377)
  • immune system phenotype
  • enlarged lymph nodes
    • nodes become massively enlarged when TET is stopped; when TET is given to mice in advanced stages of disease, complete regression of enlarged lymph nodes occurs within 5 days   (MGI Ref ID J:72377)
  • enlarged spleen
    • spleen becomes massively enlarged when TET treatment is stopped   (MGI Ref ID J:72377)
  • increased leukocyte cell number
    • increased peripheral blood leukocyte count is observed 6-10 days after TET withdrawal; blood shows presence of cells resembling immature lymphocytes   (MGI Ref ID J:72377)
    • when TET is given to mice in advanced stages of disease, WBC counts normalize in 48-72 hours, lymphoblasts are not detected in peripheral blood   (MGI Ref ID J:72377)
  • cellular phenotype
  • increased apoptosis
    • spleen becomes massively enlarged   (MGI Ref ID J:72377)
  • skeleton phenotype
  • abnormal bone marrow morphology
    • bone marrow is pale; hematopoietic cells are replaced by lymphoblasts   (MGI Ref ID J:72377)
  • tumorigenesis
  • increased leukemia incidence
    • 100% of mice develop acute lymphoblastic leukemia (ALL) upon withdrawal of tetracycline administration   (MGI Ref ID J:72377)
    • leukocyte counts range from 80000-150000/ul   (MGI Ref ID J:72377)
    • leukemic cells infiltrate skin, pleura, and meninges   (MGI Ref ID J:72377)

Tg(tetO-BCR/ABL1)2Dgt/0 Tg(Tal1-tTA)19Dgt/0

        involves: C57BL/6 * DBA/2 * FVB/N
  • mortality/aging
  • premature death   (MGI Ref ID J:96511)
  • hematopoietic system phenotype
  • abnormal hematopoiesis
    • 12 days after BCR/ABL induction, bone marrow shows a 7-fold increase in hematopoietic stem cells and a 26-fold increase after 21 days; at both points, granulocyte-macrophage progenitor (GMP) percentage is increased 3-fold, while megakaryocyte-erythroid progenitors (MEP) show a 3-fold decrease   (MGI Ref ID J:96511)
    • abnormal common myeloid progenitor cell morphology
      • common myeloid precursors (CMP) show a 2-fold decrease and a 1.5-fold increase at 12 and 21 days, respectively   (MGI Ref ID J:96511)
    • abnormal lymphopoiesis
      • some mice (31%) show progression to lymphoid blast crisis with lymph node enlargement and lymphoblasts in peripheral blood; lymphooblasts are found to be arrested at different maturation stages   (MGI Ref ID J:96511)
    • increased leukocyte cell number
      • absolute number is increased 2-fold in peripheral blood 2 weeks after tet withdrawal (BCR/ABL induction)   (MGI Ref ID J:96511)
      • readministration of tet results in reversion of leukocytosis in approximately ~4 days   (MGI Ref ID J:96511)
      • increased neutrophil cell number
        • percentage and absolute number of neutrophils are increased 3- and 5- fold in peripheral blood 2 weeks after tetracycline (tet) withdrawal compared to wild-type or single transgenic mice   (MGI Ref ID J:96511)
        • readministration of tet results in reversion of neutrophilia in approximately ~4 days   (MGI Ref ID J:96511)
  • abnormal myeloblast morphology/development
    • bone marrow contains increased ratio of myeloid and erythroid cells dominated by granulocytic forms   (MGI Ref ID J:96511)
    • increase in immature myeloid cells is observed   (MGI Ref ID J:96511)
  • abnormal spleen red pulp morphology
    • after induction of BCR/ABL expression, expansion of spleen red pulp by granulocytic myeloid cells is observed at various time points   (MGI Ref ID J:96511)
  • abnormal splenic cell ratio
    • induction of BCR/ABL increases numbers of erythroid and granulocytic-monocytic progenitor cells in spleen   (MGI Ref ID J:96511)
  • enlarged spleen
    • after induction by withdrawal of tet treatment, splenomegaly invariably results   (MGI Ref ID J:96511)
    • readministration of tet results in disappearance of palpable splenomegaly   (MGI Ref ID J:96511)
  • increased bone marrow cell number
    • bone marrow of diseased mice is hypercellular   (MGI Ref ID J:96511)
    • increased numbers of cells of lymphoid and myeloid lineage are detected in diseased mice   (MGI Ref ID J:96511)
  • increased hematopoietic stem cell number
    • 12 days after BCR/ABL induction, bone marrow shows a 7-fold increase in hematopoietic stem cells   (MGI Ref ID J:96511)
  • increased megakaryocyte cell number
    • increased numbers of megakaryocytes are detected in bone marrow and spleen of diseased mice   (MGI Ref ID J:96511)
  • immune system phenotype
  • abnormal lymph node morphology
    • infiltration by myeloid cells is observed   (MGI Ref ID J:96511)
  • abnormal lymphopoiesis
    • some mice (31%) show progression to lymphoid blast crisis with lymph node enlargement and lymphoblasts in peripheral blood; lymphooblasts are found to be arrested at different maturation stages   (MGI Ref ID J:96511)
  • abnormal spleen red pulp morphology
    • after induction of BCR/ABL expression, expansion of spleen red pulp by granulocytic myeloid cells is observed at various time points   (MGI Ref ID J:96511)
  • abnormal splenic cell ratio
    • induction of BCR/ABL increases numbers of erythroid and granulocytic-monocytic progenitor cells in spleen   (MGI Ref ID J:96511)
  • enlarged spleen
    • after induction by withdrawal of tet treatment, splenomegaly invariably results   (MGI Ref ID J:96511)
    • readministration of tet results in disappearance of palpable splenomegaly   (MGI Ref ID J:96511)
  • increased leukocyte cell number
    • absolute number is increased 2-fold in peripheral blood 2 weeks after tet withdrawal (BCR/ABL induction)   (MGI Ref ID J:96511)
    • readministration of tet results in reversion of leukocytosis in approximately ~4 days   (MGI Ref ID J:96511)
    • increased neutrophil cell number
      • percentage and absolute number of neutrophils are increased 3- and 5- fold in peripheral blood 2 weeks after tetracycline (tet) withdrawal compared to wild-type or single transgenic mice   (MGI Ref ID J:96511)
      • readministration of tet results in reversion of neutrophilia in approximately ~4 days   (MGI Ref ID J:96511)
  • liver/biliary system phenotype
  • enlarged liver
    • infiltration of liver by myeloid cells is observed after induction; 57% of mice display hepatomegaly   (MGI Ref ID J:96511)
  • respiratory system phenotype
  • abnormal lung morphology
    • infiltration by myeloid cells is observed, occasionally resulting in focal pulmonary hemorrhages   (MGI Ref ID J:96511)
  • digestive/alimentary phenotype
  • abnormal small intestine morphology
    • infiltration of lamina propria by myeloid cells is observed   (MGI Ref ID J:96511)
  • tumorigenesis
  • increased lymphoma incidence
    • some mice develop lymphomas   (MGI Ref ID J:96511)
    • readministration of tet results in disappearance of lymphomas (except in 1 case)   (MGI Ref ID J:96511)
  • increased sarcoma incidence
    • 2 animals with fulminant disease displayed skin chloromas (granulocytic sarcomas)   (MGI Ref ID J:96511)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Cancer Research
Chronic Myelogenous Leukemia
Increased Tumor Incidence
      Leukemia
      Leukemia: lymphocytic

Hematological Research
Hematopoietic Defects
Immunological Defects

Immunology, Inflammation and Autoimmunity Research
Lymphoid Tissue Defects
      hematopoietic development
      myeloid hyperplasia

Research Tools
Cancer Research
      Leukemia
      Tetop Tet System
      myeloma and hybridoma production
Hematological Research
Tet Expression Systems
      tTA/rtTA Responsive Strains

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Tg(tetO-BCR/ABL1)2Dgt
Allele Name transgene insertion 2, Daniel G Tenen
Allele Type Transgenic (random, expressed)
Common Name(s) BCR-ABL; BCR-ABL stg; BCR-ABL1; TRE-BCR-ABL; TRE-BCR/ABL; TRE-P10 BCR/ABL; TRE-p210-BCR-ABL; Tg(BCR/ABL1)2Dgt; Tg(BCR/ABL1)3Dgt; p210 BCR-ABL1 transponder; p210-BCR-ABL;
Mutation Made By Daniel Tenen,   Beth Israel Deaconess Medical Center
Strain of OriginFVB/N
Expressed Gene ABL1, c-abl oncogene 1, non-receptor tyrosine kinase, human
Expressed Gene BCR, breakpoint cluster region, human
Promoter tetO, tet operator,
General Note This record is also representative of lines 3 and 4 that were also generated; all of these lines exhibit a similar phenotype in combination with Tg(MMTVtTA)1Mam.Bitransgenic mice with this transgene in combination with Tg(MMTVtTA)1Mam, when tetracycline administration is stopped, are models for B cell acute lymphoblastic leukemia (ALL); line 2 exhibits the greatest leukemia susceptibility (Figure 1). (J:72377)
Molecular Note The transgene contains a cDNA encoding the human p210 BCR-ABL1 fusion protein (B3A2 form; J:86227) under transcriptional control of the tetracycline-responsive element (tetO; also called TRE) fused to a minimal cytomegalovirus (CMV) promoter. In doubly transgenic mice expressing a tetracycline transactivator or reverse transactivator protein under control of a ubiquitous or tissue-specific promoter, expression of the BCL-ABL1 fusion gene can be controlled temporally by withdrawal or administration of a tetracycline analog. [MGI Ref ID J:72377]
 
 
 

Genotyping

Genotyping Information

Genotyping Protocols

Tg(tetO-BCR/ABL1)2Dgt, Standard PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Huettner CS; Zhang P; Van Etten RA; Tenen DG. 2000. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 24(1):57-60. [PubMed: 10615128]  [MGI Ref ID J:72377]

Additional References

Tg(tetO-BCR/ABL1)2Dgt related

Bolton-Gillespie E; Schemionek M; Klein HU; Flis S; Hoser G; Lange T; Nieborowska-Skorska M; Maier J; Kerstiens L; Koptyra M; Muller MC; Modi H; Stoklosa T; Seferynska I; Bhatia R; Holyoake TL; Koschmieder S; Skorski T. 2013. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood 121(20):4175-83. [PubMed: 23543457]  [MGI Ref ID J:198207]

Chen CI; Koschmieder S; Kerstiens L; Schemionek M; Altvater B; Pscherer S; Gerss J; Maecker HT; Berdel WE; Juergens H; Lee PP; Rossig C. 2012. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. Leukemia 26(3):465-74. [PubMed: 21904381]  [MGI Ref ID J:181529]

Eiring AM; Harb JG; Neviani P; Garton C; Oaks JJ; Spizzo R; Liu S; Schwind S; Santhanam R; Hickey CJ; Becker H; Chandler JC; Andino R; Cortes J; Hokland P; Huettner CS; Bhatia R; Roy DC; Liebhaber SA; Caligiuri MA; Marcucci G; Garzon R; Croce CM; Calin GA; Perrotti D. 2010. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 140(5):652-65. [PubMed: 20211135]  [MGI Ref ID J:160777]

Hamilton A; Helgason GV; Schemionek M; Zhang B; Myssina S; Allan EK; Nicolini FE; Muller-Tidow C; Bhatia R; Brunton VG; Koschmieder S; Holyoake TL. 2012. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 119(6):1501-10. [PubMed: 22184410]  [MGI Ref ID J:181724]

Harb JG; Neviani P; Chyla BJ; Ellis JJ; Ferenchak GJ; Oaks JJ; Walker CJ; Hokland P; Roy DC; Caligiuri MA; Marcucci G; Huettner CS; Perrotti D. 2013. Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target. Leukemia 27(10):1996-2005. [PubMed: 23670294]  [MGI Ref ID J:201846]

Huettner CS; Koschmieder S; Iwasaki H; Iwasaki-Arai J; Radomska HS; Akashi K; Tenen DG. 2003. Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome. Blood 102(9):3363-70. [PubMed: 12855552]  [MGI Ref ID J:86227]

Koschmieder S; Gottgens B; Zhang P; Iwasaki-Arai J; Akashi K; Kutok JL; Dayaram T; Geary K; Green AR; Tenen DG; Huettner CS. 2005. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 105(1):324-34. [PubMed: 15331442]  [MGI Ref ID J:96511]

Reynaud D; Pietras E; Barry-Holson K; Mir A; Binnewies M; Jeanne M; Sala-Torra O; Radich JP; Passegue E. 2011. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 20(5):661-73. [PubMed: 22094259]  [MGI Ref ID J:178950]

Schemionek M; Elling C; Steidl U; Baumer N; Hamilton A; Spieker T; Gothert JR; Stehling M; Wagers A; Huettner CS; Tenen DG; Tickenbrock L; Berdel WE; Serve H; Holyoake TL; Muller-Tidow C; Koschmieder S. 2010. BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood 115(16):3185-95. [PubMed: 20053753]  [MGI Ref ID J:160797]

Schemionek M; Spieker T; Kerstiens L; Elling C; Essers M; Trumpp A; Berdel WE; Muller-Tidow C; Koschmieder S. 2012. Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML. Leukemia 26(5):1030-7. [PubMed: 22193968]  [MGI Ref ID J:188980]

Schepers K; Pietras EM; Reynaud D; Flach J; Binnewies M; Garg T; Wagers AJ; Hsiao EC; Passegue E. 2013. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 13(3):285-99. [PubMed: 23850243]  [MGI Ref ID J:201668]

Sengupta A; Arnett J; Dunn S; Williams DA; Cancelas JA. 2010. Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo. Blood 116(1):81-4. [PubMed: 20407032]  [MGI Ref ID J:162808]

Sengupta A; Ficker AM; Dunn SK; Madhu M; Cancelas JA. 2012. Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells. Blood 119(2):494-502. [PubMed: 22101899]  [MGI Ref ID J:181793]

Tilli MT; Furth PA. 2003. Conditional mouse models demonstrate oncogene-dependent differences in tumor maintenance and recurrence. Breast Cancer Res 5(4):202-5. [PubMed: 12817992]  [MGI Ref ID J:84503]

Zhang B; Strauss AC; Chu S; Li M; Ho Y; Shiang KD; Snyder DS; Huettner CS; Shultz L; Holyoake T; Bhatia R. 2010. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17(5):427-42. [PubMed: 20478526]  [MGI Ref ID J:160523]

Health & husbandry

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Colony Maintenance

Breeding & HusbandryWhen maintaining a live colony, transgenic mice are bred together or to wildtype siblings.

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $2450.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.
    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice
    Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $3185.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.
    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice
    Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Control Information

  Control
   Noncarrier
   001800 FVB/NJ
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.5)